Biogen (NASDAQ:BIIB) Downgraded by Zacks Research to Strong Sell

Zacks Research cut shares of Biogen (NASDAQ:BIIB) from a hold rating to a strong sell rating in a research report released on Monday,Zacks.com reports.

A number of other equities analysts also recently weighed in on the stock. Wall Street Zen raised shares of Biogen from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Guggenheim raised their price objective on shares of Biogen from $246.00 to $260.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. UBS Group raised shares of Biogen from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $185.00 to $225.00 in a research report on Wednesday, April 22nd. Freedom Capital upgraded shares of Biogen from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 1st. Finally, JPMorgan Chase & Co. increased their target price on shares of Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Biogen currently has a consensus rating of “Moderate Buy” and a consensus price target of $217.41.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $216.06 on Monday. The company has a market capitalization of $31.90 billion, a PE ratio of 23.18 and a beta of 0.20. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The stock’s 50 day moving average price is $194.96 and its 200-day moving average price is $186.27. Biogen has a twelve month low of $121.05 and a twelve month high of $219.72.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.Biogen’s revenue was up 1.9% on a year-over-year basis. During the same period last year, the business posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities analysts anticipate that Biogen will post 13.95 EPS for the current year.

Hedge Funds Weigh In On Biogen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BIIB. Reflection Asset Management purchased a new stake in shares of Biogen during the 4th quarter valued at approximately $25,000. WPG Advisers LLC grew its stake in Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares in the last quarter. First Horizon Corp bought a new stake in Biogen during the 4th quarter valued at $30,000. WFA of San Diego LLC bought a new stake in Biogen during the 2nd quarter valued at $32,000. Finally, Root Financial Partners LLC lifted its position in shares of Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 123 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Needham raised its price target on Biogen to $256 and reiterated a Buy rating, citing stronger-than-expected Spinraza HD momentum and progress across the company’s pipeline. Biogen: Key Takeaways From Needham’s Meeting With Top Management
• Positive Sentiment: Biogen said it will showcase new Alzheimer’s disease data at AAIC 2026, including Phase 2 CELIA results for diranersen and additional lecanemab analyses, which could reinforce confidence in one of its key growth areas. Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026
• Positive Sentiment: Biogen was highlighted alongside other biotech leaders hitting new 52-week highs, reflecting broader sector strength and momentum in the stock. Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
• Neutral Sentiment: Zacks added Biogen-related ticker BBIB to its Strong Sell list, but this appears to be a separate ticker and not a direct negative on Biogen Inc. itself. New Strong Sell Stocks for June 30th
• Negative Sentiment: One report said Biogen is trimming Apellis-related R&D spending and pausing or ending investment in most legacy programs after its acquisition, which may raise integration and capital-allocation concerns. Biogen trims Apellis pipeline and R&D team after $5.6bn takeover
• Negative Sentiment: Biogen was also mentioned in a class action settlement notice, which could keep some legal overhang on the shares, though the announcement itself is not a new operational setback. Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.